Raymond James Financial Services Advisors’s ANI Pharmaceuticals ANIP Stock Holding History

Raymond James Financial Services Advisors’s Portfolio ANIP Stock Details ANIP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-2,694	Closed	-$221K	–	2821
2019 Q2	$221K	Sell	2,694 -265	-9%	-$18.8K	﹤0.01%	2469
2019 Q1	$209K	Buy	+2,959	New	+$174K	﹤0.01%	2477
2018 Q3	–	Sell	-3,913	Closed	-$261K	–	2815
2018 Q2	$261K	Buy	+3,913	New	+$244K	﹤0.01%	2328
2017 Q4	–	Sell	-10,023	Closed	-$526K	–	2539
2017 Q3	$526K	Buy	10,023 +530	+6%	+$25.3K	﹤0.01%	1678
2017 Q2	$444K	Buy	9,493 +3,837	+68%	+$185K	﹤0.01%	1748
2017 Q1	$280K	Buy	+5,656	New	+$318K	﹤0.01%	1939
2016 Q4	–	Sell	-6,131	Closed	-$407K	–	2348
2016 Q3	$407K	Sell	6,131 -15	-0.2%	-$938	﹤0.01%	1607
2016 Q2	$343K	Buy	+6,146	New	+$299K	﹤0.01%	1635

Other funds holding ANIP

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Mangrove Partners Greenwich, Connecticut $1.52B AUM 36.54% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Nomura Holdings Tokyo, Japan $85.4B AUM 91.09% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

ICOM

Investment Counselors of Maryland Baltimore, Maryland $4.37B AUM 76.25% 1-Year Est. Return

First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return

Raymond James Financial Services Advisors's ANIP Position: Q3 2019 in Review

Raymond James Financial Services Advisors sold out of ANI Pharmaceuticals (ANIP) in Q3 2019, closing a stake of 2,694 shares — an estimated $221K sold.

Raymond James Financial Services Advisors first reported a position in ANIP in Q2 2016 and held it in 8 quarters. The position peaked at $526K in Q3 2017. 190 funds tracked by Wall St. Rank hold ANIP as of Q3 2019.

Raymond James Financial Services Advisors reported no remaining ANI Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
Raymond James Financial Services Advisors sold 2,694 ANI Pharmaceuticals shares in Q3 2019, an estimated $221K.
Raymond James Financial Services Advisors first reported a position in ANI Pharmaceuticals in Q2 2016 and held it in 8 quarters.
Raymond James Financial Services Advisors's ANI Pharmaceuticals position peaked at $526K in Q3 2017.
190 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q3 2019.

Based on Raymond James Financial Services Advisors's 13F filing for Q3 2019, filed 7 Nov 2019.